<DOC>
	<DOCNO>NCT02386553</DOCNO>
	<brief_summary>The primary objective study examine efficacy multiple dos Nusinersen administer intrathecally prevent delay need respiratory intervention death infant genetically diagnose presymptomatic spinal muscular atrophy ( SMA ) . Secondary objective study examine effect Nusinersen infant genetically diagnose presymptomatic SMA .</brief_summary>
	<brief_title>A Study Multiple Doses Nusinersen ( ISIS 396443 ) Delivered Infants With Genetically Diagnosed Presymptomatic Spinal Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Age ≤ 6 week first dose Genetic documentation 5q SMA homozygous gene deletion mutation compound heterozygous mutation . Genetic documentation 2 3 copy survival motor neuron 2 ( SMN2 ) . Ulnar compound muscle action potential ( CMAP ) ≥ 1 mV Baseline . Gestational age 37 42 week singleton birth ; gestational age 34 42 week twin . Meet additional study relate criterion . Key Hypoxemia ( oxygen saturation &lt; 96 % awake asleep without supplemental oxygen respiratory support ) . Any clinical sign symptom Screening immediately prior first dosing ( Day 1 ) , opinion Investigator , strongly suggestive SMA . Clinically significant abnormality hematology clinical chemistry parameter . Treatment investigational drug give treatment SMA biological agent , device . Any history gene therapy , prior antisense oligonucleotide ( ASO ) treatment , cell transplantation . Meet additional study relate criterion . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NURTURE</keyword>
</DOC>